Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial

Journal of Clinical Oncology

Volumn 31, Issue 35, 2013, Pages 4438-4444

  Hironaka, Shuichi ^a   Ueda, Shinya ^b   Yasui, Hirofumi ^c   Nishina, Tomohiro ^d   Tsuda, Masahiro ^e   Tsumura, Takehiko ^f   Sugimoto, Naotoshi ^g   Shimodaira, Hideki ⁱ   Tokunaga, Shinya ^h   Moriwaki, Toshikazu ^j   Esaki, Taito ^k   Nagase, Michitaka ^l   Fujitani, Kazumasa ⁱ   Yamaguchi, Kensei ^m   Ura, Takashi ⁿ   Hamamoto, Yasuo ^o,p   Morita, Satoshi ^q   Okamoto, Isamu ^b   Boku, Narikazu ^r   Hyodo, Ichinosuke ^j  

^a CHIBA CANCER CENTER   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^e HYOGO CANCER CENTER   (Japan)

^f OSAKA RED CROSS HOSPITAL   (Japan)

^g OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^h OSAKA CITY GENERAL HOSPITAL   (Japan)

ⁱ OSAKA NATIONAL HOSPITAL   (Japan)

^j TOHOKU UNIVERSITY HOSPITAL   (Japan)

^k UNIVERSITY OF TSUKUBA   (Japan)

^l NATIONAL KYUSHU CANCER CENTER   (Japan)

^m JICHI MEDICAL UNIVERSITY   (Japan)

ⁿ SAITAMA CANCER CENTER   (Japan)

^o AICHI CANCER CENTER HOSPITAL   (Japan)

^p TOCHIGI CANCER CENTER   (Japan)

^q YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^r ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROPYRIMIDINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN; PACLITAXEL; VASCULOTROPIN ANTIBODY; CAMPTOTHECIN; FLUOROURACIL; PLATINUM; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED ANEMIA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPONATREMIA; JAPAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERITONEUM METASTASIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMACH CANCER; STOMACH PERFORATION; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANEMIA; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; STOMACH NEOPLASMS; TREATMENT FAILURE; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; STOMACH TUMOR;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; PLATINUM; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84891372637     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.5805     Document Type: Article

References (25)

1. Murad AM, Santiago FF, Petroianu A, et al: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41, 1993 (Pubitemid 23182046)
2. Glimelius B, Hoffman K, Haglund U, et al: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5:189-190, 1994 (Pubitemid 24062577)
3. Pyrhönen S, Kuitunen T, Nyandoto P, et al: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591, 1995
4. Cunningham D, Starling N, Rao S, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46, 2008
5. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
6. Kang YK, Kang WK, Shin DB, et al: Capecitabine/ cisplatin versus 5-fluorouracil/cisplatin as firstline therapy in patients with advanced gastric cancer: A randomised phase III noninferiority trial. Ann Oncol 20:666-673, 2009
7. Ajani JA, Rodriguez W, Bodoky G, et al: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial. J Clin Oncol 28:1547-1553, 2010
8. Ohtsu A, Shah MA, Van Cutsem E, et al: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29:3968-3976, 2011
9. Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 9:215-221, 2008
10. Boku N, Yamamoto S, Fukuda H, et al: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study. Lancet Oncol 10:1063-1069, 2009
11. Narahara H, Iishi H, Imamura H, et al: Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 14:72-80, 2011
12. Yamada Y, Shirao K, Ohtsu A, et al: Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 12:1133-1137, 2001 (Pubitemid 32834495)
13. Yamaguchi K, Tada M, Horikoshi N, et al: Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 5:90-95, 2002 (Pubitemid 34832243)
14. Taguchi T, Sakata Y, Kanamaru R, et al: Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: A Japanese Cooperative Study Group trial (group A) [in Japanese]. Gan To Kagaku Ryoho 25:1915-1924, 1998
15. Arai T, Hamaguchi T, Shirao K: Weekly paclitaxel in patients with heavily treated advanced gastric cancer. Proc Am Soc Clin Oncol 22:321, 2003 (suppl; abstr 1291)
16. Hironaka S, Zenda S, Boku N, et al: Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 9:14-18, 2006
17. Kodera Y, Ito S, Mochizuki Y, et al: A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res 27:2667-2671, 2007 (Pubitemid 47227980)
18. Matsuda G, Kunisaki C, Makino H, et al: Phase II study of weekly paclitaxel as a second-line treatment for S-1-refractory advanced gastric cancer. Anticancer Res 29:2863-2867, 2009
19. Hamaguchi T, Shirao K, Ohtsu A, et al: A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidineresistant advanced gastric cancer: A report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial). Gastric Cancer 14:226-233, 2011
20. Giuliani F, Molica S, Maiello E, et al: Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: A phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106). Am J Clin Oncol 28:581-585, 2005 (Pubitemid 41790010)
21. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
22. Thuss-Patience PC, Kretzschmar A, Bichev D, et al: Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer: A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47:2306-2314, 2011
23. Kang JH, Lee SI, Lim DH, et al: Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513-1518, 2012
24. Ji SH, Lim do H, Yi SY, et al: A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. BMC Cancer 9:110, 2009
25. Kim J, Sun CL, Mailey B, et al: Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol 21:152-160, 2010